This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NIH Awards New England Biolabs A Phase II SBIR Grant For The Research And Development Of Novel Enzymes For Epigenetic Studies

IPSWICH, Mass., Nov. 8, 2012 /PRNewswire/ -- New England Biolabs (NEB) has recently received a $640,000 Phase II Small Business Innovation Research (SBIR) grant to expand its research and product development of novel enzymatic tools for epigenetic analysis. This latest grant adds to the more than $1.1 million of SBIR funds awarded for this research since 2009.

(Logo:  http://photos.prnewswire.com/prnh/20090921/NE79207LOGO-b )

Since its establishment in 1974, NEB has been dedicated to the discovery and development of reagents for the life sciences industry. A key to this effort has been the focused development of recombinant enzyme technology by NEB scientists, resulting in  a wide array of enhanced tools for molecular biology research and analysis, such as engineered restriction enzymes with greater specificity under a wider range of reaction conditions. This commitment has placed NEB at the forefront of restriction enzyme research and supply.

The use of restriction enzymes in epigenetic studies has been a research focus at NEB for many years. Specifically, research in the area of methylation-dependent and methylation-sensitive restriction enzymes has led to the discovery and commercialization of new tools to identify these DNA modifications. For example, in 2010, NEB scientists identified the MspJI family of restriction enzymes, which has the ability to excise small fragments of methylated DNA for use in epigenetics studies. This latest SBIR grant award enables further research in this area, and ultimately a deeper understanding of epigenetic marks in the mammalian genome.

"Since its founding, NEB has coupled its basic research with the development of new tools for molecular biology," states Dr. Bill Jack, Director of Research at NEB. "The repository of knowledge, generated during the almost four decades of restriction endonuclease study at NEB, has fueled a discovery program that has radically expanded the utility of restriction endonucleases and activity on a variety of DNA templates, including those created by epigenetic modification. We are committed to continuing this discovery process, and to use these novel new enzymes to uncover the role of epigenetic modification during development, differentiation and disease." 

For more information on the use of restriction enzymes in epigenetics research, visit www.epimark.com.

SOURCE New England Biolabs

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,654.77 +369.26 2.27%
S&P 500 1,987.66 +47.15 2.43%
NASDAQ 4,812.7080 +115.1720 2.45%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs